tsx:th
|
66356
|
Mar 1st, 2020 12:00AM
|
Theratechnologies
|
1.6K
|
92.00
|
Open
|
Pharmaceuticals
|
Feb 29th, 2020 08:11PM
|
Feb 29th, 2020 08:11PM
|
Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies' strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV.
|
Open
|
|
Open
|
2310 Alfred-Nobel Blvd.
|
Montreal
|
Quebec
|
CA
|
H4S 2B4
|
|
Theratechnologies
|
|
|
tsx:th
|
66356
|
Feb 28th, 2020 12:00AM
|
Theratechnologies
|
1.6K
|
92.00
|
Open
|
Pharmaceuticals
|
Feb 28th, 2020 04:54PM
|
Feb 28th, 2020 04:54PM
|
Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies' strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV.
|
Open
|
|
Open
|
2310 Alfred-Nobel Blvd.
|
Montreal
|
Quebec
|
CA
|
H4S 2B4
|
|
Theratechnologies
|
|
|
tsx:th
|
66356
|
Feb 27th, 2020 12:00AM
|
Theratechnologies
|
1.6K
|
92.00
|
Open
|
Pharmaceuticals
|
Feb 27th, 2020 01:54AM
|
Feb 27th, 2020 01:54AM
|
Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies' strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV.
|
Open
|
|
Open
|
2310 Alfred-Nobel Blvd.
|
Montreal
|
Quebec
|
CA
|
H4S 2B4
|
|
Theratechnologies
|
|
|
tsx:th
|
66356
|
Feb 26th, 2020 12:00AM
|
Theratechnologies
|
1.6K
|
92.00
|
Open
|
Pharmaceuticals
|
Feb 26th, 2020 03:29PM
|
Feb 26th, 2020 03:29PM
|
Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies' strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV.
|
Open
|
|
Open
|
2310 Alfred-Nobel Blvd.
|
Montreal
|
Quebec
|
CA
|
H4S 2B4
|
|
Theratechnologies
|
|
|
tsx:th
|
66356
|
Feb 25th, 2020 12:00AM
|
Theratechnologies
|
1.6K
|
92.00
|
Open
|
Pharmaceuticals
|
Feb 25th, 2020 02:18PM
|
Feb 25th, 2020 02:18PM
|
Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies' strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV.
|
Open
|
|
Open
|
2310 Alfred-Nobel Blvd.
|
Montreal
|
Quebec
|
CA
|
H4S 2B4
|
|
Theratechnologies
|
|
|
tsx:th
|
66356
|
Feb 24th, 2020 12:00AM
|
Theratechnologies
|
1.6K
|
92.00
|
Open
|
Pharmaceuticals
|
Feb 24th, 2020 12:45PM
|
Feb 24th, 2020 12:45PM
|
Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies' strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV.
|
Open
|
|
Open
|
2310 Alfred-Nobel Blvd.
|
Montreal
|
Quebec
|
CA
|
H4S 2B4
|
|
Theratechnologies
|
|
|
tsx:th
|
66356
|
Feb 23rd, 2020 12:00AM
|
Theratechnologies
|
1.6K
|
92.00
|
Open
|
Pharmaceuticals
|
Feb 23rd, 2020 05:08PM
|
Feb 23rd, 2020 05:08PM
|
Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies' strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV.
|
Open
|
|
Open
|
2310 Alfred-Nobel Blvd.
|
Montreal
|
Quebec
|
CA
|
H4S 2B4
|
|
Theratechnologies
|
|
|
tsx:th
|
66356
|
Feb 22nd, 2020 12:00AM
|
Theratechnologies
|
1.6K
|
93.00
|
Open
|
Pharmaceuticals
|
Feb 22nd, 2020 04:03PM
|
Feb 22nd, 2020 04:03PM
|
Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies' strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV.
|
Open
|
|
Open
|
2310 Alfred-Nobel Blvd.
|
Montreal
|
Quebec
|
CA
|
H4S 2B4
|
|
Theratechnologies
|
|
|
tsx:th
|
66356
|
Feb 21st, 2020 12:00AM
|
Theratechnologies
|
1.6K
|
93.00
|
Open
|
Pharmaceuticals
|
Feb 20th, 2020 08:00PM
|
Feb 21st, 2020 01:41PM
|
Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies' strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV.
|
Open
|
|
Open
|
2310 Alfred-Nobel Blvd.
|
Montreal
|
Quebec
|
CA
|
H4S 2B4
|
|
Theratechnologies
|
|
|
tsx:th
|
66356
|
Feb 19th, 2020 12:00AM
|
Theratechnologies
|
1.6K
|
93.00
|
Open
|
Pharmaceuticals
|
Feb 19th, 2020 12:52PM
|
Feb 19th, 2020 12:52PM
|
Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies' strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV.
|
Open
|
|
Open
|
2310 Alfred-Nobel Blvd.
|
Montreal
|
Quebec
|
CA
|
H4S 2B4
|
|
Theratechnologies
|
|
|